Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 11/20 | 0.43 |
| ▸ | CA2 | P00918 | 11/20 | 0.43 |
| ▸ | CA9 | Q16790 | 8/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 7/20 | 0.38 |
| ▸ | CA6 | P23280 | 4/20 | 0.38 |
| ▸ | CA7 | P43166 | 3/20 | 0.38 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.38 |
| ▸ | CA4 | P22748 | 3/20 | 0.38 |
| ▸ | CA5A | P35218 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31527702 | 0.97 | CA2 (0.42) | CA1CA2CA9MAPK1FTO | |
| Trimethylammonium SCHEMBL27851715 | 0.90 | CA2 (0.38) | CA1CA2CA9MAPK1FTO | |
| Pyridine SCHEMBL9838377 | 0.88 | NAPRT (0.41) | CA1CA2CA9MAPK1FTO | |
| Pyrrole SCHEMBL27616550 | 0.86 | CA2 (0.36) | CA1CA2CA9MAPK1FTO | |
| Pyrazole SCHEMBL27514785 | 0.81 | CA1 (0.33) | CA1CA2CA9MAPK1FTO | |
| Trifluoroacetic Acid SCHEMBL28163458 | 0.81 | L3MBTL1 (0.41) | CA1CA2CA9MAPK1FTO | |
| SCHEMBL28576 | 0.79 | CA1 (0.33) | CA1CA2CA9MAPK1FTO | |
| Imidazole SCHEMBL8354987 | 0.79 | ALDH1A1 (0.48) | CA1CA2CA9MAPK1FTO | |
| 1,2,4-Triazole SCHEMBL6053442 | 0.78 | CA1 (0.32) | CA1CA2CA9MAPK1CYP1A2 | |
| SCHEMBL5593062 | 0.75 | TXNRD1 (0.37) | CA1CA2CA9MAPK1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 664 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025102245-A1 | SYNTHESIS METHOD FOR DUAL ENDOTHELIN RECEPTOR ANTAGONIST APROCITENTAN | 浙江天宇药业股份有限公司 | 2025-05-22 | — | — | WO | claimed |
| CN-117736152-A | Synthesis method of dual endothelin receptor antagonist apixitan | 浙江天宇药业股份有限公司 | 2024-03-22 | — | — | CN | claimed |
| EP-3860998-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | ANNAPURNA BIO INC (US) | 2023-12-27 | — | — | EP | claimed |
| CN-109633065-B | Method for detecting drug residues in animal body | 沈阳海关技术中心 | 2021-04-20 | — | — | CN | claimed |
| EP-3255043-B1 | N-(6-((2R,3S)-3,4-DIHYDROXYBUTAN-2-YLOXY)-2-(4-FLUOROBENZYLTHIO)PYRIMIDIN-4-YL)-3- METHYLAZETIDINE-1-SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR | ASTRAZENECA AB (SE) | 2021-01-20 | — | — | EP | claimed |
| US-9975881-B2 | Compound | ASTRAZENECA AB (SE) | 2018-05-22 | — | — | US | claimed |
| US-20160108023-A1 | Novel Compound | ASTRAZENECA AB (SE) | 2016-04-21 | — | — | US | claimed |
| CN-103781781-B | N-(6-((2R, 3S)-3,4-dihydroxyl fourth-2-base oxygen base)-2-(4-Fluorobenzylthio) pyrimidine-4-yl as chemokine receptor modulators)-3-methyl azetidine-1-sulphonamide | ASTRAZENECA AB (SE) | 2015-08-26 | — | — | CN | claimed |
| US-20140228339-A1 | Novel Compound | ASTRAZENECA AB (SE) | 2014-08-14 | — | — | US | claimed |
| US-8735413-B2 | Compound | ASTRAZENECA AB (SE) | 2014-05-27 | — | — | US | claimed |
| CN-1081815-A | Safe with pyrazolyl sulfonylureas of activity of weeding | MONSANTO CO (US) | 1994-02-16 | — | — | CN | claimed |
| CN-1075846-A | Chemically stabilized herbicidal oil-based suspensions | ISHIHARA SANGYO KAISHA (JP) | 1993-09-08 | — | — | CN | claimed |
| CN-1068824-A | N-pyrazolyl-1, 2, 4-triazolo [1, 5-c ] pyrimidine-2-sulfonamides as herbicides | DOWELANCO (US) | 1993-02-10 | — | — | CN | claimed |
| CN-1063015-A | Safe herbicidal sulfonamide compositions | MONSANTO CO (US) | 1992-07-29 | — | — | CN | claimed |
| CN-1054251-A | 5,7-dihydroxyl-1,2, the preparation method of 4-triazolo [1,5-a] pyrimidine-2-sulfonanilide | DOWELANCO (US) | 1991-09-04 | — | — | CN | claimed |
| CN-1051561-A | Preparation 5-methyl-N-aryl-1,2, the aqueous process of 4-triazolo [1,5-a] pyrimidine-2-sulfonamides | DOWELANCO (US) | 1991-05-22 | — | — | CN | claimed |
| EP-0142152-B1 | Novel substituted 1,2,4-triazolo- [1,5-a] pyrimidine-2-sulfonamides and compositions and methods of controlling undesired vegetation and suppressing the nitrification of ammonium nitrogen in soil | THE DOW CHEMICAL COMPANY (US) | 1991-03-20 | — | — | EP | claimed |
| EP-0343752-A1 | Alkoxy-1,2,4-triazolo (1,5-c) pyrimidine-2-sulfonamides, process for their preparation and intermediates | DowElanco (US) | 1989-11-29 | — | — | EP | claimed |
| EP-0337947-A1 | Triazolylsulfonamides | CIBA-GEIGY AG (CH) | 1989-10-18 | — | — | EP | claimed |
| CN-1031174-A | Herbicidal combinations | ISHIHARA SANGYO KAISHA (JP) | 1989-02-22 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228339-A1 | Novel Compound | CXCR2, CXCR1, CCR5 | CA1 3867/4885CA2 2395/4885CA9 2447/4885 |
| US-20160108023-A1 | Novel Compound | CXCR2, CXCR1, CCR5 | CA1 3867/4885CA2 2395/4885CA9 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.